Algorae Pharmaceuticals Limited

As of June 30, 2024, Algorae Pharmaceuticals Limited carries a market capitalization of 16.87M, placing it among publicly traded companies globally. Its enterprise value stands at 13.77M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2024, Algorae Pharmaceuticals Limited has 1.69B shares outstanding.

These figures are as of June 30, 2024.

As of June 30, 2024, Algorae Pharmaceuticals Limited maintains a current ratio of 30.78, meaning it holds 30.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2024, Algorae Pharmaceuticals Limited posted a negative return on equity (ROE) of -61.85, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -35.74, reflecting losses generated across the asset base.

As of the close on October 23, 2026, Algorae Pharmaceuticals Limited's stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.

These figures cover the twelve months ended June 30, 2024. EBITDA reached -2.20M, while operating income came in at -2.20M.

These figures are as of June 30, 2024. Total book value stands at 3.01M, with working capital of 5.31M providing operational flexibility.

These figures cover the twelve months ended June 30, 2024. Total shareholder yield is negative at -3.10, meaning Algorae Pharmaceuticals Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Algorae Pharmaceuticals Limited's most recent stock split took place on March 23, 2023 with a 80:81 split ratio.